AbbVie to develop amylin analog for obesity treatment in $350m licensing deal with Gubra

AbbVie has taken a significant step into obesity treatment through a licensing agreement with Denmark-based Gubra, a company specializing in peptide-based drug discovery. The deal ... Read More